杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/03/23 | 2,075 | 2,075 | 2,040 | 2,040 | -31 | -1.5% | 167,900 |
2021/03/22 | 2,052 | 2,073 | 2,050 | 2,071 | +28 | +1.4% | 132,000 |
2021/03/19 | 2,049 | 2,062 | 2,030 | 2,043 | +17 | +0.8% | 225,000 |
2021/03/18 | 2,021 | 2,040 | 2,005 | 2,026 | -16 | -0.8% | 165,100 |
2021/03/17 | 2,020 | 2,042 | 2,014 | 2,042 | +23 | +1.1% | 152,000 |
2021/03/16 | 1,990 | 2,025 | 1,985 | 2,019 | +33 | +1.7% | 228,400 |
2021/03/15 | 1,973 | 1,986 | 1,967 | 1,986 | +19 | +1% | 133,700 |
2021/03/12 | 1,963 | 1,973 | 1,951 | 1,967 | -6 | -0.3% | 146,300 |
2021/03/11 | 1,975 | 1,985 | 1,966 | 1,973 | +2 | +0.1% | 105,200 |
2021/03/10 | 1,977 | 1,977 | 1,962 | 1,971 | -10 | -0.5% | 104,800 |
2021/03/09 | 1,953 | 1,988 | 1,946 | 1,981 | +40 | +2.1% | 186,400 |
2021/03/08 | 1,945 | 1,948 | 1,930 | 1,941 | +5 | +0.3% | 114,400 |
2021/03/05 | 1,917 | 1,938 | 1,906 | 1,936 | +15 | +0.8% | 135,400 |
2021/03/04 | 1,924 | 1,927 | 1,913 | 1,921 | -5 | -0.3% | 110,800 |
2021/03/03 | 1,939 | 1,939 | 1,919 | 1,926 | -6 | -0.3% | 104,100 |
2021/03/02 | 1,918 | 1,940 | 1,915 | 1,932 | +4 | +0.2% | 111,800 |
2021/03/01 | 1,927 | 1,928 | 1,907 | 1,928 | +38 | +2% | 112,600 |
2021/02/26 | 1,915 | 1,917 | 1,890 | 1,890 | -22 | -1.2% | 150,800 |
2021/02/25 | 1,938 | 1,941 | 1,912 | 1,912 | -8 | -0.4% | 103,400 |
2021/02/24 | 1,931 | 1,934 | 1,913 | 1,920 | -11 | -0.6% | 105,100 |
2021/02/22 | 1,923 | 1,938 | 1,915 | 1,931 | +27 | +1.4% | 76,900 |
2021/02/19 | 1,914 | 1,966 | 1,893 | 1,904 | -19 | -1% | 182,200 |
2021/02/18 | 1,937 | 1,943 | 1,923 | 1,923 | -5 | -0.3% | 112,400 |
2021/02/17 | 1,928 | 1,939 | 1,927 | 1,928 | +2 | +0.1% | 94,700 |
2021/02/16 | 1,945 | 1,945 | 1,921 | 1,926 | -16 | -0.8% | 142,200 |
2021/02/15 | 1,955 | 1,955 | 1,935 | 1,942 | -4 | -0.2% | 86,000 |
2021/02/12 | 1,953 | 1,961 | 1,941 | 1,946 | -9 | -0.5% | 109,600 |
2021/02/10 | 1,964 | 1,968 | 1,951 | 1,955 | -21 | -1.1% | 94,400 |
2021/02/09 | 1,955 | 1,976 | 1,951 | 1,976 | +21 | +1.1% | 126,200 |
2021/02/08 | 1,948 | 1,963 | 1,941 | 1,955 | +5 | +0.3% | 116,300 |
2021/02/05 | 1,941 | 1,957 | 1,928 | 1,950 | -1 | -0.1% | 149,500 |
2021/02/04 | 1,961 | 1,976 | 1,940 | 1,951 | -25 | -1.3% | 164,600 |
2021/02/03 | 1,948 | 1,976 | 1,945 | 1,976 | +35 | +1.8% | 98,800 |
2021/02/02 | 1,953 | 1,962 | 1,940 | 1,941 | -24 | -1.2% | 82,300 |
2021/02/01 | 1,950 | 1,970 | 1,942 | 1,965 | +2 | +0.1% | 74,800 |
2021/01/29 | 1,971 | 2,000 | 1,963 | 1,963 | -17 | -0.9% | 131,800 |
2021/01/28 | 1,976 | 1,994 | 1,971 | 1,980 | -28 | -1.4% | 104,500 |
2021/01/27 | 1,976 | 2,008 | 1,968 | 2,008 | +40 | +2% | 106,300 |
2021/01/26 | 1,976 | 1,983 | 1,965 | 1,968 | +10 | +0.5% | 100,100 |
2021/01/25 | 1,950 | 1,960 | 1,931 | 1,958 | +44 | +2.3% | 133,300 |
2021/01/22 | 1,950 | 1,950 | 1,914 | 1,914 | -48 | -2.4% | 148,500 |
2021/01/21 | 1,954 | 1,973 | 1,951 | 1,962 | ±0 | ±0% | 69,700 |
2021/01/20 | 1,947 | 1,964 | 1,937 | 1,962 | +15 | +0.8% | 91,000 |
2021/01/19 | 1,976 | 1,977 | 1,947 | 1,947 | -9 | -0.5% | 118,100 |
2021/01/18 | 1,966 | 1,973 | 1,952 | 1,956 | -8 | -0.4% | 70,100 |
2021/01/15 | 1,966 | 1,979 | 1,959 | 1,964 | -2 | -0.1% | 85,900 |
2021/01/14 | 1,960 | 1,976 | 1,956 | 1,966 | +3 | +0.2% | 100,800 |
2021/01/13 | 1,965 | 1,971 | 1,952 | 1,963 | -20 | -1% | 103,300 |
2021/01/12 | 1,974 | 1,989 | 1,968 | 1,983 | +16 | +0.8% | 127,200 |
2021/01/08 | 1,948 | 1,978 | 1,941 | 1,967 | +19 | +1% | 118,100 |
901~
950
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
栄研化 | 209,200円 | +0.4% | -8.4% | 2.53% | 27.65倍 | 1.57倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム